Phase 2 Study of Capecitabine-Temozolomide(CapTem) with yttrium-90 Radioembolization in the Treatment of Patients with Unresectable Metastatic Grade 2 Neuroendocrine Tumors

The research study is being conducted to determine if combining two treatments for liver metastases from neuroendocrine tumors (NETs), oral chemotherapy (CapTem) and transarterial radioembolization (TARE), will improve tumor control in the liver. You will be asked to take CapTem for two weeks every month. Radioembolization will be done during the second and third month while taking the chemotherapy. You will get scans every 3 months to see how much your tumors shrink and for how long this response lasts. Your participation will last for two years or until your liver disease progresses. You may benefit from participation if the combined treatments work better than a single treatment, but this is unknown. The most common risks are the side effects of CapTem (low blood counts, fatigue, nausea, skin reactions) and radioembolization (fatigue, nausea, fever, pain). If you do not wish to participate in this trial, your Interventional Oncology and Medical Oncology NET doctors will discuss other standard treatments for your disease

You may be eligible for this study if you meet the following criteria:

• Conditions:
  cancer,tumor
• Age: Between 18 Years - 90 Years
• Gender: All